z-logo
Premium
A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy
Author(s) -
Hurria Arti,
Hurria Anju,
Zuckerman Enid,
Panageas Katherine S.,
Fornier Monica,
D'Andrea Gabriella,
Dang Chau,
Moasser Mark,
Robson Mark,
Seidman Andrew,
Currie Violante,
VanPoznak Catherine,
Theodoulou Maria,
Lachs Mark S.,
Hudis Clifford
Publication year - 2006
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1111/j.1532-5415.2006.00789.x
Subject(s) - medicine , chemotherapy , breast cancer , cancer , geriatric oncology , prospective cohort study , regimen , chemotherapy regimen , quality of life (healthcare) , anthracycline , toxicity , cohort , cyclophosphamide , oncology , surgery , nursing
OBJECTIVES: To examine the toxicity experienced by a cohort of older women receiving adjuvant chemotherapy for breast cancer and the longitudinal effect on their functional status and quality of life (QOL). DESIGN: A geriatric assessment measuring functional status, comorbidity, mood, nutritional status, and QOL was performed before chemotherapy, at the end of chemotherapy, and 6 months later. SETTING: This prospective longitudinal study was conducted at Memorial Sloan‐Kettering Cancer Center, New York, New York. PARTICIPANTS: Fifty patients aged 65 and older with Stage I to III breast cancer receiving any adjuvant chemotherapy; 49 were evaluable. MEASUREMENTS: The chemotherapy regimen and the toxicity to chemotherapy were recorded. A geriatric assessment was performed before the start of chemotherapy, on completion of chemotherapy, and 6 months after completion of chemotherapy. QOL testing was performed at the same times. RESULTS: Patients (mean age 68, range 65–84) received an anthracycline‐based chemotherapy regimen (n=15) or cyclophosphamide 600 mg/m 2 intravenously (IV), methotrexate 40 mg/m 2 IV, 5‐fluorouracil 600 mg/m 2 IV every 3 weeks for eight cycles (n=34). Grade 3 or 4 toxicity occurred in 53% (n=26), hematological toxicity in 27% (n=13), and nonhematological toxicity in 31% (n=15). Despite toxicity, there was no significant longitudinal change in functional status or QOL. CONCLUSION: Despite toxicity from adjuvant chemotherapy, this cohort of relatively young older patients maintained their functional status and QOL from before chemotherapy to 6 months postchemotherapy. Subtle changes in higher‐order functioning would require assessment using different geriatric assessment tools.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here